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Improving Aerosol Drug Delivery in CF therapy 
S. SeemamL A. Schmitt, R. Waldner, M. Hug, M. I~acch 
PARI AerosoI Research Institute, Munich, Germany 
Aims: The PARI LC PLUS ® jet nebulizer is the approved elivery systena for TOBI ® 
(300 mg tobramycin i  5mL) to treat pseudomonas et uginosa infections in CF patients. 
"Die eFlow~t apid electronic nebulizer (PARI GmbH) has been adopted from the eFlow ®
deliveiy platform and optimized for achninisttation f currently approved medications 
used hi CE Tbis study was under taken to investigate he in vitro aerosol cbm acteristics 
of the eFlow®i apid with TOBI* compm ed to the LC PLUS ®. 
Methods: Delivered (DD) and Respit able Doses (RD) were measured dining simulated 
breathing (tidal volume 500 ml, 15 bi eathshnin, inhal./exhal, ratio 1:1 ). "Ihe droplet size 
distribution was assessed by laser dift~action (Malvern MasteiSizeiX) at a constant 
flow of 20 lhnin. 
Results: DD and RD me both higher with eFlow®iapid compared to LC PLUS ®, 
howeveL drag mass of coarse (> 5pro) and very fine ch oplets (< 2pro) is 17% and 57% 
less for eFlowet apid vs. LC PLUS ®. Tbis indicates higher lung deposition at the desired 
site of action and reduced side effects due to lower oropbaryngeal deposition mid 
systenaic absoiption. Respit able Drug Deliver y Rate is 2.6 fold highei; thus allowing for 
a significmitly shorter nebulization time with TOBI®/eFlowet apid (6.8rain vs. 13.3rain). 
e Flow*h apid pARY LC PLUS ~ 
Mean Mean 
DD [rag] 1311 1142 
RD [rag < 5 bin] 952 717 
[rag < 2 bin] 87 201 
[rag > 5 bin] 358 431 
RDDR [rag < 5 bin/rain] 140 54 
Nebulization Time [rain] 68 133 
MMD [~m] 389 400 
GSD 153 200 
RF [% < 5~m] 731 623 
Conclusions: The eFlowetapid electronic nebulizer sbows a high RDDR and 
significantly reduced treatment time with TOBI e (5 ml  volume fill) whicb is essential 
for an effective and convenient inhalation thet apy. Tbis is important with respect o 
patient compliance mid, thereby, may improve therapeutic efficacy. Oilier medications 
used hi CF wil l  be further investigated. 
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Is the Gee repeat polymorphic length in the Multidrug resistance- 
associated protein 1 (MRP1) gene relevant for regulaSng 
transcripSonal acSvity constitutively and in response to azithromycin 
(AZM)? 
E. Nicolis, M. Pasetto, C. Cigana, U. Pr adal, B .M. Assael, P. Melotti  
Cystic Fibrosis Center-Azienda Ospedaliera, V~rona-ltaly 
MRPs exhibit homology with CFFR, which is defective in CF. Higher levels of 
MRP1 mRNA have been associated to less severe CF phenotype as wel l  as to 
beneficial effects of AZM ha CF patients. MRPI has been considered either as 
potential modifier gene and/or as novel target for pbarmacotherapy of CF, in 
particular for AZM. We previously described a polymorpbic length of the GCC 
repeat in the 5'untraslated region of the MRPI gene (alleles ranging from 7 to 14 
triplets). 
Since the repeat is ha a region involved ha regulation of MRPI expression we 
hypothesized a functional relevance of this poly morpbism. 
In this study we compared the transcriptional ctivity of the proximal MRPI 
5'regulatory region containing 7 or 14 GCC triplets. To this end gene reporter 
studies were performed in a CF airway epithelial cell l ine ha basal conditions and in 
the presence of AZM. The two alleles do not show slatistically significant 
differences in transcriptional ctivity; AZM treatment does not significantly affect 
transcriptional ctivity. 
In our experimental conditions the sequence responsible for variable levels of 
MRPI mRNA detected in other studies seems not to be included ha the DNA 
sequence we analyzed. However, we still can not exclude a functional relevance of 
this polymotphism on MRPI expression. Additional sequences as wel l  as conditions 
to whom the cells can be exposed in vivo that can have an effect on MRPI 
expression remain to be investigated. Our experimental model might be useful for 
testing other molecules potentially relevant for therapy of CF. 
Supported by Ital ian Cystic Fibrosis Research Foundation and Legge 548/93 
Finanziamento Ricerca Fibrosi Cistica 2004. 
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Azithromycin (AZM) inhibits Nuclear Factor-kB (NF-kB) activity and 
expression of interleukin 8 (IL8) in CF airway epithelial cells 
C. Cigana, E. Nicolis, M. Pasetto, B .M. Assael, P. Melotti  
Cystic Fibrosis Center-Azienda Ospedaliera di V~rona, V~rona-ltaly 
CF airways are characterized by exaggerated i l l f lammation. This condition 
correlates with activation of the NF kB pathway associated with production of ILS, 
the major polymotpbonuclear leukocyte chemokine in the lung. Higher IL8 levels 
are described ha CF than ha non CF cells. AZM has been reported to ameliorate 
airway inf lammation ha CF patients. We previously demonstrated that AZM inhibits 
IL8 expression in a CF cell l ine. 
This study was aimed to investigate whether AZM affects NF kB activity ha the 
same cells and whether the same effects are detectable in another cell line. 
IL  8 mRNA levels were determined by quantitative r a l4 ime PCR based analysis. 
Amounts o f l L  8 secreted were detected in supemat ant s by ELISA. 
We have found that AZM is capable of reducing constitutive IL 8 mRNA expression 
as wel l  as protein secretion in both CF cell lines. 
In this study we found an about 40% reduction of IL 8 mRNA expression levels 
(n 9, p<0.05) and an about 50% reduction of IL8 release (n~4, p<0.05). 
Since IL  8 is considered a NF kB target gene, we  then hypothesized an eventual 
effect of AZM on the activation of this transcription factor in both cell lines. NF kB 
activity was evaluated as DNA binding by an ELISA based format assay. We 
determined a statistically significant reduction of about 50% of DNA binding 
activity in the presence of AZM in both cell lines. 
These results support the anti i l l f lammatory role of this macrolide, ha particular 
inhibition of NF kB activity suggests other pro i l l f lammatory genes regulated by 
this transcription factor as potential target of AZM relevant for therapy of CF. 
Supported by Ital ian Cystic Fibrosis Research Foundation and Legge 548/93 
Finanziamento Ricerca Fibr osi Cistica 2004. 
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Long-term low-dose therapy with macrolides in bronchopulmonary 
disease in Cystic Fibrosis (CF) pediatric paSents 
A.M. Radionovitch 1,N.J. Kashir skaya ~, N.I. Kapr anov 3 
Research Centre for Medical Genetics RAMS, oscow, Russia 
The aim was to evaluate the potential effect of long4erm administration of 
macrolides on clinical, functional and laboratory parameters, uch as FVC, FEV1, 
weight/height index (Wt/Ht%), Schwachman and Brasfield scores (SBs), chest X 
ray, bronchopulmonary exacerbations (BPE), microbiology and i l l f lammatory 
markers (TNF cq IL  8, IL 4, IFN % neutrophil elastase activity and protein 
concentration) in the sputum and plasma. 
85 children with CF (39 m) aged av. 12 years 2 months (6,0 16,5 years) were 
assigned to three cl in ical ly comparable groups: I (n 30) treated w i th  
clarithromycine (250 mg every other day for 12 months); II (n 25) treated with 
azifl lromycin (250 mg three times a week  for 18 months); II I (control) (n 30) on 
basic therapy. 
Results: After 6 months of treatment, group I became statistically better than those 
in III group in the fol lowing tests: FEV1 (78.1+8.3% vs. 59.9+8.6%, p<0.01), FVC 
(84.5+7.2% vs. 68.1+7.8%, p<0.01) and Wt/Ht% (91.2+4.9% vs. 84.2+4.3%, 
p<0.05). Parameters in group I remained stable within the fol lowing 6 months. In 
group II, rel iable differences with the control group were obtained only after 12 
months: FEV1 (86.8+17.6% vs. 58.2+9.0%, p 0.05), FVC (89.0+18.8% vs. 
66.7+7.8%, p~).05), SBs (72.3+8.6 vs. 58.1+7.6,p~3.05) and remained stable to the 
end of the trial; after 18 months there was a difference in Wt/Ht% also (90.8+7.6% 
vs. 84.0+3.9%, p<0.05). There was a remarkable decrease ha frequency of BPE in 
groups I and II. 
We observed significant decreases in TNF c( (p 0.02), IL 8 (p 0.03), II 4 (p<0.01), 
IFN'/(p<0.CO1) ha the sputum and a decrease of IL 4 in the plasma (p~).CO2) in 
group I. 
Conclusion: a beneficial effect of long term low dose therapy with macrolides is 
proved by functional and immtmological changes. 
